Research
Standard Risk B-Precursor Acute Lymphoblastic Leukemia
Protocol Description
This 2-part study compares the event-free survival of pediatric patients with newly diagnosed, standard risk average B-precursor acute lymphoblastic leukemia (ALL) treated with induction therapy followed by 1 of 4 intensified phases of post-induction therapy. Participation in the ALL Classification Study (IRB 405121) will provide doctors with the subtype of ALL by the end of the induction therapy phase, which will determine therapy assignment for the second part of this study. This international, multi-center study will enroll approximately 3,500 participants with 50 enrolled through Children’s Hospital of Pittsburgh of UPMC.
Eligibility Criteria
Children that have been recently diagnosed with acute lymphoblastic leukemia will be asked to participate in Part 1 of this study. Participants will then be offered chemotherapy based upon their subtypes for Part 2 of this study.
Boys: 1 to 9 years
Girls: 1 to 9 years
Requirements
Participants will be given various physical exams, organ function tests and medical procedures throughout the length of the study, which are part of regular care for patients with ALL.
Visits: Number will depend on treatment regimen
Duration: 2.5 to 3.5 years
Status: Study Suspended
Source of Support
Children’s Oncology Group
National Cancer Institute
Additional Resources
Children’s Oncology Group CureSearch
Study Description at National Institutes of Health
Primary Investigator(s)
A. Kim Ritchey, MD
Contact Information
To get started, please contact:
A. Kim Ritchey, MD
412-692-5055
